Serum Institute of India will play pivotal role in development of COVID-19 vaccines
By MYBRANDBOOK
Serum Institute of India (SII) is the world’s largest vaccine producer in terms of volume. SII is currently working on three candidates for COVID-19, including the testing of its recombinant-BCG vaccine in Phase 3 clinical trials at several locations across India. With these, SII continues to play a pivotal role in the development and commercialization of COVID-19 vaccines, says GlobalData, a leading data and analytics company.
Krishna Srinivasaraghavan, Pharma Analyst at GlobalData, says: “Serum Institute of India has invested US$100m for setting up a COVID-19 vaccine manufacturing unit in India. SII is highly active on three fronts – development, partnerships and manufacturing capabilities to supply COVID-19 vaccines.”
Earlier, New York Institute of Technology (NYIT) researchers highlighted that countries without universal policies of BCG vaccination have been more severely affected compared to countries with universal and long-standing BCG policies. It is important to note that BCG vaccination is part of the national immunization program in India and the majority of the Asian countries.
Vakzine Projekt Management GmbH (VKM), in which SII is the majority stake holder, has initiated a Phase 3 trial of VPM1002 (BCG vaccine) in May 2020, involving 1,200 healthcare professionals globally and around 6,000 high-risk subjects in India (NCT04387409 and CTRI/2020/04/024749). It is expected to be completed in April 2021.
According to GlobalData’s Pharma Intelligence Center, overall, 19 trials are being conducted globally at various locations to test the use of BCG vaccine against COVID-19, especially focused on healthcare workers. These include a Phase 3 ongoing trial being conducted by Murdoch Children’s Research Institute (BRACE trial) in Australia (NCT04327206), which is expected to enrol around 10,000 subjects and complete by October 2020. Trials are also being planned in India by JIPMER (CTRI/2020/04/024833) in Phase III and Haffkine Institute (CTRI/2020/05/025013) to test a BCG vaccine in Phase II for COVID-19.
Srinivasaraghavan concludes: “BCG vaccinnation is already part of the compulsory schedule for children in India. If the BCG trials for COVID-19 are successful, the vaccine can be extended to a wider population in the fight against the pandemic effectively and save lives. Moreover, SII would be able to scale-up the production of BCG vaccine quickly in India.”
Singapore to remove One-Time Passwords from Bank Accounts
According to the Monetary Authority of Singapore, clients who utilise secur...
Is 375 million Airtel subscribers database breached?
When a hacker claims to have accessed and put up for sale a customer databa...
The government of India intends to construct a single portal f
A single portal will be launched by the Indian government to list all of it...
OpenAI offers GPT-4o, a faster model available to all users at
GPT-4o, a faster and more sophisticated AI model, is made available to all...
Icons Of India : GAUTAM ADANI CHAIRMAN ADANI GROUP
Gautam Adani is the Founder and Chairman of the Adani Group, which ran...
Icons Of India : Anil Kumar Lahoti
Anil Kumar Lahoti, Chairman, Telecom Regulatory Authority of India (TR...
Icons Of India : NEERAJ MITTAL
He started his career as an IAS Officer in 1992. He has held various a...
BEL - Bharat Electronics Limited
BEL is an Indian Government-owned aerospace and defence electronics co...
IOCL - Indian Oil Corporation Ltd.
IOCL is India’s largest oil refining and marketing company ...
GeM - Government e Marketplace
GeM is to facilitate the procurement of goods and services by various ...
Indian Tech Talent Excelling The Tech World - JAYASHREE ULLAL, President and CEO - Arista Network
Jayshree V. Ullal is a British-American billionaire businesswoman, ser...
Indian Tech Talent Excelling The Tech World - Sundar Pichai, CEO- Alphabet Inc.
Sundar Pichai, the CEO of Google and its parent company Alphabet Inc.,...
Indian Tech Talent Excelling The Tech World - Dheeraj Pandey, CEO, DevRev
Dheeraj Pandey, Co-founder and CEO at DevRev , has a remarkable journe...